UroGen Pharma Ltd. (NASDAQ:URGN) Given Consensus Rating of “Buy” by Brokerages

Shares of UroGen Pharma Ltd. (NASDAQ:URGNGet Free Report) have been given a consensus rating of “Buy” by the six brokerages that are covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $43.70.

A number of equities research analysts have issued reports on URGN shares. Oppenheimer reiterated an “outperform” rating and issued a $40.00 price target on shares of UroGen Pharma in a research note on Wednesday, October 16th. EF Hutton Acquisition Co. I raised UroGen Pharma to a “strong-buy” rating in a research note on Monday, October 14th. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of UroGen Pharma in a report on Tuesday, October 15th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a report on Friday, December 6th.

Check Out Our Latest Research Report on UroGen Pharma

UroGen Pharma Trading Down 2.2 %

Shares of NASDAQ:URGN opened at $10.52 on Tuesday. The stock has a 50 day moving average of $11.84 and a 200 day moving average of $13.71. The company has a market cap of $246.74 million, a PE ratio of -3.34 and a beta of 1.06. UroGen Pharma has a 12-month low of $10.26 and a 12-month high of $20.70. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGNGet Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.29. The firm had revenue of $25.20 million during the quarter, compared to the consensus estimate of $24.22 million. During the same quarter in the previous year, the company earned ($0.68) earnings per share. As a group, equities research analysts expect that UroGen Pharma will post -3.1 EPS for the current year.

Hedge Funds Weigh In On UroGen Pharma

Several institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. boosted its position in shares of UroGen Pharma by 120.3% during the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock valued at $41,099,000 after acquiring an additional 1,337,257 shares during the last quarter. Millennium Management LLC raised its stake in UroGen Pharma by 2,672.0% during the second quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock valued at $19,480,000 after purchasing an additional 1,119,019 shares in the last quarter. Cowen AND Company LLC lifted its position in UroGen Pharma by 29.1% during the second quarter. Cowen AND Company LLC now owns 2,099,482 shares of the company’s stock valued at $35,229,000 after purchasing an additional 472,893 shares during the last quarter. Vestal Point Capital LP purchased a new position in shares of UroGen Pharma in the 3rd quarter worth $5,080,000. Finally, Great Point Partners LLC increased its holdings in shares of UroGen Pharma by 10.9% in the 2nd quarter. Great Point Partners LLC now owns 2,906,259 shares of the company’s stock worth $48,767,000 after buying an additional 285,714 shares during the last quarter. Hedge funds and other institutional investors own 91.29% of the company’s stock.

About UroGen Pharma

(Get Free Report

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

Recommended Stories

Analyst Recommendations for UroGen Pharma (NASDAQ:URGN)

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.